A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
Completed
AbbVie
Phase 2/Phase 3
2015-06-22
This was a long-term follow-up study to evaluate the durability of sustained virologic
response (SVR), persistence of direct-acting antiviral agent (DAA) resistance, and clinical
outcomes for participants who received glecaprevir (ABT-493) and/or pibrentasvir (ABT-530) in
prior AbbVie Phase 2 or 3 clinical studies for the treatment of chronic hepatitis C virus
(HCV) infection.
Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P
Recruiting
AbbVie
Phase 3
2016-06-01
An open label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir,
dasabuvir with or without ribavirin or glecaprevir/pibrentasvir for people with recently
acquired hepatitis C virus infection with or without HIV co-infection.
Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P
Recruiting
Kirby Institute
Phase 3
2016-06-01
An open label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir,
dasabuvir with or without ribavirin or glecaprevir/pibrentasvir for people with recently
acquired hepatitis C virus infection with or without HIV co-infection.
A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)
Completed
AbbVie
Phase 3
2016-04-22
The purpose of this study is to assess the safety and efficacy of 12 weeks of treatment of
ABT-493/ABT-530 (glecaprevir/pibrentasvir) in adults who are post primary orthotopic liver or
renal transplant with chronic hepatitis C virus (HCV) infection.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
